Live feed08:00:00·19mPRReleasevia QuantisnowCalidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic SummitByQuantisnow·Wall Street's wire, on your screen.CLDI· Calidi Biotherapeutics Inc.Health Care
